Short answer
Pacira BioSciences, Inc. (PCRX) filed an 8-K current report with the SEC on June 11, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Stockholders approved ESPP expansion, reserving 800,000 additional common shares for employee purchases.
Pacira BioSciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Stockholders approved ESPP expansion, reserving 800,000 additional common shares for employee purchases
- Increased share authorization creates potential future dilution but supports employee equity participation
- Board immediately reassigned committee memberships across Audit, People & Compensation, and Nominating committees
- Alethia Young, Michael Yang, and Christopher J. Christie appointed committee chairs respectively
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Company nominees won all three Class III director seats; DOMA Perpetual Capital Management nominees were rejected
- Samit Hirawat and Thomas Wiggans received 27,950,304 and 28,044,841 votes, respectively
- KPMG LLP ratification passed decisively with 32,908,044 votes for
- Executive compensation vote passed narrowly, 19,513,224 for versus 13,073,321 against
- Stock incentive plan failed, while employee stock purchase plan passed with 29,089,928 votes for
Item 8.01 · Other Events
- Pacira issued an Annual Meeting press release on June 9, 2026
- Exhibit 99.1 contains the substantive meeting-related information for investor review
Item EX-99.1 · Exhibit EX-99.1
- Stockholders preliminarily elected all three Pacira nominees: Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans
- Board outcome supports management’s ability to pursue Pacira’s 5x30 strategy and broader non-opioid pain portfolio
- Final certified voting results will follow in a subsequent Form 8-K
- No immediate financial terms or operating changes disclosed; investor impact centers on governance continuity
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Pacira BioSciences, Inc. 8-K filings
Get the next PCRX 8-K as it lands
Follow PCRX for push alerts, or ask the research agent what this filing means.